Home | Seer Seer: See the proteome in a way that’s never been possible before

From a pinhole to a panorama

To create a more transformative view of the proteome, we had to create a new technology—one that provides a path for researchers to survey without bias the millions of proteoforms (protein variants) thought to exist within individuals and across populations. To accomplish this, robust measurements must be done across orders of magnitude of protein abundance and across populations over time – with a methodology that is both rapid and scalable. While technologies exist today that can provide one or more of these attributes, Seer is the first to combine them all into a single, efficient workflow.

Seer technology allows you to see the proteome in new ways with:

Broad affinity range:

Reproducible and selective binding without prior knowledge, using engineered nanoparticles that allow unbiased interrogation of protein variants

Quantitative compression of the dynamic range renders low abundant proteins visible to detectors

Tunable physiochemical properties:

Nearly infinite combination of distinct nanoparticle designs to survey the full richness of proteoform diversity

Extendable to a portfolio of assays that seamlessly integrate into the Proteograph product suite

Robust, simple, and scalable:

Reproducible performance across samples, labs, and experiments

Automated, easy to use, and scalable workflow eliminates the need for lengthy and costly depletion and fractionation required with existing processes, making it simple to see the proteome complexity

We empower the scientific community through the power of proteomics

At Seer, we develop innovative solutions that act as a gateway to the proteome. Our goal is to empower the scientific community with tools to achieve exceptional scientific outcomes. We do this by removing the technological barriers that stand between breakthrough ideas and the information that can make them a reality.

We’re committed to eliminating the obstacles that have kept the potential of proteomics from matching the pace of advancements we’ve seen in other fields, like genomics and transcriptomics. We believe that unbiased, deep, rapid, large-scale proteomics can, and must, become accessible to the broad scientific community so that we may significantly advance our understanding of biology, health, and disease.

Learn what Seer’s approach can mean for your research

Publications & News

First name Last name

Title goes here

Philip Ma is the Chief Business Officer for Seer. Previously, he was Vice-President for Digital Health Technologies and Data Sciences at Biogen, a group that he established in 2015 to discover insights and create value for Biogen and its patients. Prior to joining Biogen, Philip was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice for the Firm. Active in community affairs, Philip also serves on the Board of Committee of 100, a group of Chinese-American business and community leaders focused on U.S. China relations and the Asian-American experience. Before McKinsey, Philip was a macromolecular crystallographer in the lab of Dr. Carl O. Pabo at Massachusetts Institute of Technology, where he received his Ph.D. in Biology. Philip also has degrees in Biochemistry (A.B. from Harvard College) and in Economics (MPhil from Oxford University, where he was a Rhodes Scholar).